VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | VITAL results for birtamimab in AL amyloidosis

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses the results of the phase III VITAL study of birtamimab (NEOD001), a monoclonal IgG1 antibody, plus standard of care in patients with light chain (AL) amyloidosis. Post hoc analyses suggest a potential survival benefit with NEOD001 for AL amyloidosis patients with the highest risk of early mortality (Mayo stage IV). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter